^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Bioferon (interferon alpha 2b)

    Associations

    News

    Trials
    Company:
    Biosidus
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    6ms
    Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov)
    P1/2, N=12, Recruiting, Roswell Park Cancer Institute | Trial completion date: Dec 2025 --> Jun 2025 | Trial primary completion date: Dec 2025 --> Jun 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    Keytruda (pembrolizumab) • Ampligen (rintatolimod) • Bioferon (interferon alpha 2b) • celecoxib oral
    10ms
    Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov)
    P1/2, N=12, Recruiting, Roswell Park Cancer Institute | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 expression • PD-L1 negative
    |
    Keytruda (pembrolizumab) • Ampligen (rintatolimod) • Bioferon (interferon alpha 2b) • celecoxib oral
    1year
    Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov)
    P1/2, N=12, Not yet recruiting, Roswell Park Cancer Institute | Trial completion date: Jun 2025 --> Dec 2025 | Initiation date: Sep 2023 --> Dec 2023 | Trial primary completion date: Jun 2025 --> Dec 2025
    Trial completion date • Trial initiation date • Trial primary completion date • Metastases
    |
    PD-L1 expression • PD-L1 negative
    |
    Keytruda (pembrolizumab) • Ampligen (rintatolimod) • Bioferon (interferon alpha 2b) • celecoxib oral
    over1year
    Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov)
    P1/2, N=12, Not yet recruiting, Roswell Park Cancer Institute | Trial completion date: Jul 2027 --> Jun 2025 | Trial primary completion date: Jul 2026 --> Jun 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 expression • PD-L1 negative
    |
    Keytruda (pembrolizumab) • Ampligen (rintatolimod) • Bioferon (interferon alpha 2b) • celecoxib oral
    over1year
    Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov)
    P1/2, N=12, Not yet recruiting, Roswell Park Cancer Institute | Trial completion date: Apr 2027 --> Jul 2027 | Trial primary completion date: Apr 2026 --> Jul 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 expression • PD-L1 negative
    |
    Keytruda (pembrolizumab) • Ampligen (rintatolimod) • Bioferon (interferon alpha 2b) • celecoxib oral